|
Match
|
Document |
Document Title |
|
|
6652890 |
Tea catechins as cancer specific proliferation inhibitors
The invention described herein encompasses a methods and compositions of treating cancer or solid tumors comprising the administration of a therapeutically effective amount of catechins, a group of...
|
|
|
6649189 |
Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells
A hematopoietic growth factor delivery composition includes a hematopoietic growth factor, a liquid vehicle, a first biocompatible polymer and a second biocompatible polymer. The composition...
|
|
|
6645527 |
Stabilized sustained release tramadol formulations
A stabilized sustained release oral solid dosage form which includes an effective amount of tramadol or a pharmaceutically acceptable salt thereof dispersed in a matrix of a hydrophobic material...
|
|
|
6646014 |
Organic compounds
The present invention concerns a method for the control of various diseases in bee-hives by applying to the bee-hives an effective amount of an essential oil in a slow-release formulation whereby...
|
|
|
6645526 |
Storage stable thyroxine active drug formulations and methods for their production
This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an...
|
|
|
6641840 |
Sustained release formulations for growth hormone secretagogues
The present invention relates to formulations for administering a growth hormone secretagogue. More specifically, the present invention relates to sustained release formulations for administering a...
|
|
|
6642276 |
Controlled release macrolide pharmaceutical formulations
Disclosed is an oral controlled release macrolide pharmaceutical formulation. In a preferred embodiment, the formulation comprises a citrate salt of a preferred macrolide, clarithromycin. Also...
|
|
|
6638534 |
Preparation capable of releasing drug at target site in intestine
A preparation capable of releasing a medicinal substance at a targeted site in the intestine, wherein the preparation dose not releases medicinal substance in endogastri at all, but can quickly...
|
|
|
6638532 |
Tetracycline—doxycycline antibiotic composition
An antibiotic product for delivering at least Tetracycline or Doxycycline that is comprised of three dosage forms with different release profiles with each of Tetracycline and Doxycycline being...
|
|
|
6635279 |
Active ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and production
The present invention relates to oral dosage forms comprising a) one or more active ingredientsb) a formulated mixture of polyvinyl acetate and polyvinylpyrrolidonec) where appropriate other...
|
|
|
6635280 |
Extending the duration of drug release within the stomach during the fed mode
Drugs are formulated as unit oral dosage forms by incorporating them into polymeric matrices comprised of hydrophilic polymers that swell upon imbibition of water to a size that is large enough to...
|
|
|
6635237 |
Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substance dependence
The present invention relates to a pharmaceutical composition comprising cocaethylene as active ingredient and to its use in treating dependence on psychoactive substances, in particular on cocaine.
|
|
|
6635281 |
Gastric retaining oral liquid dosage form
The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of a liquid, active agent formulation to a fluid...
|
|
|
6632451 |
Delayed total release two pulse gastrointestinal drug delivery system
A two pulse gastrointestinal delivery system is provided. The system comprises a desired agent in combination with a swellable core material, the core being surrounded by an inner coat of a...
|
|
|
6632453 |
Ciprofoxacin-metronidazole antibiotic composition
An antibiotic product for delivering at least Ciprofoxacin or Metronidazole that is comprised of three dosage forms with different release profiles with each of Ciprofoxacin and Metronidazole being...
|
|
|
6630165 |
Methods for providing effective reboxetine therapy with once-a-day dosing
Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine...
|
|
|
6630162 |
Pharmaceutical formulation and its use
The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the...
|
|
|
6627222 |
Amoxicillin-dicloxacillin antibiotic composition
An antibiotic product for delivering at least Amoxicillin or dicloxacillin that is comprised of three dosage forms with different release profiles with each of Amoxicillin and dicloxacillin being...
|
|
|
6623758 |
Cephalosporin-metronidazole antibiotic composition
An antibiotic product for delivering at least cephalosporin or Metronidazole that is comprised of three dosage forms with different release profiles with each of cephalosporin and Metronidazole...
|
|
|
6623754 |
Dosage form of N-acetyl cysteine
A directly-compressed, controlled release tablet contains N-acetyl cysteine as the active ingredient.
|
|
|
6623755 |
Pharmaceutical tablets
The present invention relates to novel pharmaceutical tablets useful for administering pharmaceutical active ingredients, such as bisphosphonates. These tablets have improved surface properties...
|
|
|
6620617 |
Polymeric gene delivery system
A means for obtaining efficient introduction of exogenous genes into a patient, with long term expression of the gene, is disclosed. The gene, under control of an appropriate promoter for...
|
|
|
6620434 |
Sustained release dosage form unit having latex coating and method of making the same
Dosage form unit is provided to deliver one or more beneficial agents into a fluid, such as liquid enteral nutritional product. The dosage form unit includes a core containing at least one...
|
|
|
6620431 |
Shellac film coatings providing release at selected pH and method
Film coatings for enteric and colonic release at selected pH are provided by selecting and/or formulating a shellac of a predetermined acid number. The method includes the selection of the acid...
|
|
|
6610323 |
Oral pharmaceutical pulsed release dosage form
An enteric coated pharmaceutical dosage form comprising an H+,K+-ATPase inhibitor is disclosed. The dosage form comprises at least two portions of the H+,K+- ATPase inhibitor to be released in at...
|
|
|
6610328 |
Amoxicillin-clarithromycin antibiotic composition
An antibiotic product for delivering at least Amoxicillin or Clarithromycin that is comprised of three dosage forms with different release profiles with each of Amoxicillin and Clarithromycin being...
|
|
|
6607748 |
Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
The present invention relates to a novel form of cross-linked high amylose starch and processes for its manufacture. Such cross-linked high amylose starch is useful as an excipient in a...
|
|
|
6605303 |
Oral pharmaceutical extended release dosage form
An enteric coated pharmaceutical extended release dosage form of a H+, K+-ATPase inhibitor giving an extended plasma concentration profile of a H+, K+-ATPase inhibitor. The extended plasma profile...
|
|
|
6602521 |
Multiplex drug delivery system suitable for oral administration
A multiplex drug delivery system suitable for oral administration containing at least two distinct drug dosage packages, which exhibit equivalent dissolution profiles for an active agent when...
|
|
|
6599531 |
Method of making ibuprofen and narcotic analgesic compositions
Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising...
|
|
|
6599511 |
Pharmaceutical composition containing desoxypeganine for the treatment of drug dependence
Desoxypeganine and its pharmaceutically acceptable acid addition salts can be used in the treatment of drug addiction or drug dependence. Said substances are administered preferably in a continuos...
|
|
|
6599532 |
Osmotic device containing alprazolam and an antipsychotic agent
The present invention provides an osmotic device containing controlled release alprazolam in the core optionally in combination with an anti-psychotic agent, in a rapid release external coat. A...
|
|
|
6599529 |
Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs)
An oral pharmaceutical modified release multiple-units composition for the administration of a therapeutically and/or prophylactically effective amount of a non-steroid anti-inflammatory drug...
|
|
|
6596314 |
Controlled release liquid active agent formulation dosage forms
Controlled release of liquid, active agent formulations is provided by dispersing porous particles containing the liquid active agent formulation in osmotic, push-layer dosage forms. The dosage...
|
|
|
6596311 |
Fast disintegrating tablets
This invention provides a formulation for preparing a fast disintegrating tablet comprising a drug in multiparticulate form, one or more water insoluble inorganic excipients, one or more...
|
|
|
6592897 |
Slow release tablet prepared from linear water-insoluble polysacchrides
The invention relates to a controlled release tablet which in part or as a whole contains water-insoluble linear polysaccharides, preferably the polysaccharide poly(1,4-α-D-glucan), in the form of ...
|
|
|
6592895 |
Biodegradable polyhydric alcohol esters
Precursor polyhydric alcohol esters where acyl moieties originate from aliphatic homopolymer or copolymer polyesters and contain free hydroxyl at their terminal ends, are reacted to provide...
|
|
|
6592902 |
Controlled release eplerenone compositions
The invention relates to oral pharmaceutical compositions useful as aldosterone receptor blockers comprising the active agent micronized eplerenone in an amount of about 10 mg to about 1000 mg and...
|
|
|
6586005 |
Extended release formulation of etodolac
A sustained release formulation of etodolac for once daily administration is described.
|
|
|
6582734 |
Antimicrobial composition useful for the treatment of bovine mastitis
The present invention relates to a two-part antimicrobial composition comprising at least one chlorine dioxide generating component comprising at least one metal chlorite and at least one...
|
|
|
6579536 |
Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient
The invention relates to a solid, sustained-release pharmaceutical composition for oral administration containing tilidine mesylate as active ingredient.
|
|
|
6576258 |
Pharmaceutical formulation with controlled release of active substances
There is disclosed a method for stabilizing active substances that are unstable in acidic medium, unstable when stored for longer periods of time in the presence of water and at the same time...
|
|
|
6576259 |
Sustained release formulations containing tacrolimus
Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15...
|
|
|
6576260 |
Sustained-release form of administration containing tramadol saccharinate
Disclosed herein is sustained-release formulations of tramadol comprising tramadol saccharinate coated with at least one sustained-release coating. The sustained release formulations may also...
|
|
|
6572889 |
Controlled release solid dosage carbamazepine formulations
A polymer or copolymer composition derived from one or more unsaturated carboxylic acids that is cross-linked and carbamazepine in conjunction with conventional materials such as fillers,...
|
|
|
6573238 |
Method for producing sustained-release formulations
Methods for preparing biodegradable microparticles are provided. Also provided are microparticles prepared by the method which include IGF-1 entrapped therein. The microparticles allow for...
|
|
|
6569456 |
Osmotic device containing diltiazem and an ACE inhibitor or diuretic
The present invention provides an osmotic device containing controlled release diltiazem in the core in combination with a rapid release ACE inhibitor, or diuretic, in an external coat. The...
|
|
|
6565883 |
Controlled release oral compositions comprising rivastigmine
Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.
|
|
|
6558700 |
Multiple-unit sustained release tablets
A multiple-unit sustained release tablet characterized by consisiting of a granular part and a powdery part, each granule comprising a matrix composed of a water-insoluble polymer and an active...
|
|
|
6558699 |
High drug load immediate and modified release oral dosage formulations and processes for their manufacture
This invention relates to high drug load granulation of (E)-α-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-
yl]methylene-2-thiophenepropionic acid in the anhydrous form, a process for its ...
|